Application of intervening basophilic granulocyte EXOSC3 in preparation of medicine for preventing or treating lupus nephritis

By interfering with the expression of EXOSC3 in basophils, the existing treatment methods for lupus nephritis have solved the problem of great side effects and ineffectiveness in some patients. By inhibiting basophil activation, the renal pathology of lupus nephritis is significantly improved, and the kidneys of lupus nephritis is very good. Disease treatment provides new targets and methods.

CN118987030AActive Publication Date: 2024-11-22AFFILIATED HOSPITAL OF GUANGDONG MEDICAL UNIV

Patent Information

Application Number
CN202410951295.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-22
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

The existing treatment methods for lupus nephritis have great side effects and are ineffective in some patients. Targeting B-cell biological agents interferes with the normal immune system, limiting their clinical application and urgently need new targets and treatment ideas.

Method used

By interfering with the expression of EXOSC3 in basophils, EXOSC3 was knocked down or knocked out by CRISPR-Cas9 technology, siRNA, shRNA and other methods, inhibiting the activation of basophils, thereby reducing the inflammatory factors IL-4, IL-6 and The expression of IL-13 reduces T cell activation levels and improves the renal pathology of lupus nephritis.

Benefits of technology

It significantly inhibits the activation of basophils, reduces the level of inflammatory factors, improves the renal pathology of lupus mice, and provides new therapeutic ideas for lupus disease mediated by basophil activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987030A_ABST
    Figure CN118987030A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicines, and discloses an application of intervening basophilic granulocyte EXOSC3 in preparation of a medicine for preventing or treating lupus nephritis, which comprises knocking down or knocking out the expression of EXOSC3. The invention finds that the expression of EXOSC3 is enhanced after basophilic granulocyte activation, and the expression is reduced after activation inhibition. After the EXOSC3 of the basophilic granulocyte is knocked down, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 of the basophilic granulocyte are obviously reduced. After the basophilic granulocyte knock-down EXOSC3 and T cells are co-cultured, the activation level of the T cells is obviously reduced. After the basophilic granulocytes knocking down the Exosc3 are adoptively transferred into a lupus mouse body, the kidney pathology is obviously improved. The invention proves that the knock-down basophilic granulocyte EXOSC3 can obviously inhibit the activation of the basophilic granulocyte EXOSC3 and improve the kidney pathology of lupus mice, thereby providing a new thought for the treatment of basophilic granulocyte activation-mediated lupus diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to the application of intervention of basophil EXOSC3 in the preparation of drugs for preventing or treating lupus nephritis. Background Art

[0002] Systemic lupus erythematosus (SLE) is a typical autoimmune disease, the main feature of which is that the patient's own immune tolerance disorder leads to an imbalance of multiple cellular immune responses in the body, such as overactivation of immune cells and the production of a large number of proinflammatory factors, which affect multiple organs and systems and cause disease. The kidney is the most commonly affected organ, namely lupus nephritis (LN). In lupus nephritis, T cells can participate in the pathological damage process through multiple pathways. First, T cells can stimulate the body to produce an inflammatory response and cause local tissue damage, thereby causing symptoms such as proteinuria and hematuria. Secondly, T cells can also promote the process of fibrosis, thereby aggravating kidney damage and deterioration of renal function. At present, the first-line drugs for lupus nephritis are hormones and immunosuppressants, such as cyclophosphamide and mycophenolate mofetil. Although they can relieve the symptoms of patients with lupus nephritis, they are ineffective for some patients with refractory lupus nephritis, and long-term use can cause serious side effects. In recent years, biological agents targeting B cells, such as those targeting B cell surface antigens or B cell stimulating factors, can improve the condition of lupus nephritis to a certain extent. However, their nonspecific clearance of B cells often interferes with the normal immune system, limiting their clinical application.

[0003] Therefore, for the treatment of lupus nephritis, there is an urgent need to explore new targets to develop safe and effective new drugs and provide new ideas for the treatment of lupus nephritis. Summary of the invention

[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and provide an application of intervening basophil EXOSC3 in the preparation of drugs for preventing or treating lupus nephritis, providing a new intervention target for inhibiting basophil activation, and providing a new approach and means for treating autoimmune diseases mediated by basophil activation.

[0005] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0006] In a first aspect, the present invention applies basophils intervened in the expression of EXOSC3 to the preparation of a drug for preventing and / or treating lupus nephritis, wherein the intervention comprises knocking down or knocking out the expression of EXOSC3.

[0007] The present invention uses human basophils as the research object, and divides them into a Control group, an Anti-IgE group, and an Anti-IgE+CQ group for proteomic detection. Subsequently, the differentially expressed proteins that mediate basophil activation are intervened, and the basophils after intervention of differentially expressed proteins are adoptively transferred into Pristane-induced lupus mice. The results show that EXOSC3 expression is enhanced after basophil activation, and expression decreases after inhibition of activation. After knocking down EXOSC3 in basophils, the expression levels of inflammatory factors IL-4, IL-6, and IL-13 are significantly reduced. After knocking down EXOSC3 in basophils and co-culturing with T cells, the activation level of T cells is significantly reduced. After adoptively transferring knockdown Exosc3 basophils into lupus mice, their renal pathology is significantly improved. The present invention confirms that knocking down basophil EXOSC3 can significantly inhibit its activation and improve the renal pathology of lupus mice, providing a new idea for the treatment of lupus disease mediated by basophil activation.

[0008] As a preferred embodiment of the application described in the present invention, the method for knocking down the expression of basophil EXOSC3 includes using CRISPR-Cas9 technology for gene editing, and using siRNA, plasmid-mediated shRNA or virus-mediated shRNA to silence EXOSC3.

[0009] As a preferred embodiment of the application of the present invention, the nucleotide sequence of the shRNA is:

[0010] GCTTAATTAGAAAGCTATTAGCTCGAGCTAATAGCTTTCTAATTAAGCTTTTT or

[0011] GGTGCTGAATCAGGTGGTTCTCTCGAGAGAACCACCTGATTCAGCACCTTTTT.

[0012] In a second aspect, the present invention uses basophil EXOSC3 as a target in the preparation of an agent for preventing and / or treating lupus nephritis.

[0013] In a third aspect, the present invention uses an inhibitor targeting basophil EXOSC3 expression in the preparation of a drug for preventing and / or treating lupus nephritis.

[0014] As a preferred embodiment of the application of the present invention, the basophils are basophils derived from peripheral blood.

[0015] In a fourth aspect, the present invention provides a preparation for preventing and / or treating lupus nephritis, comprising a substance that knocks down or knocks out the expression of basophil EXOSC3.

[0016] As a preferred embodiment of the preparation of the present invention, the substance for knocking down the expression of basophil EXOSC3 is siRNA, dsRNA, shRNA, miRNA or antisense nucleic acid.

[0017] As a preferred embodiment of the preparation of the present invention, the nucleotide sequence of the shRNA is:

[0018] GCTTAATTAGAAAGCTATTAGCTCGAGCTAATAGCTTTCTAATTAAGCTTTTT or

[0019] GGTGCTGAATCAGGTGGTTCTCTCGAGAGAACCACCTGATTCAGCACCTTTTT.

[0020] As a preferred embodiment of the preparation of the present invention, it also includes a pharmaceutically acceptable carrier.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] Basophils (Baso) play a key role in autoimmune diseases. Basophils can recognize autoreactive IgE and activate, promote the differentiation of T helper cells, and aggravate the progression of lupus nephritis. The present invention found that EXOSC3 expression was enhanced after basophil activation, and decreased after activation inhibition. After knocking down EXOSC3 in basophils, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 were significantly reduced. After knocking down EXOSC3 in basophils and co-culturing with T cells, the activation level of T cells was significantly reduced. The present invention found that basophils promote their activation through EXOSC3, thereby promoting the progression of lupus nephritis, and confirmed that knocking down basophil EXOSC3 can significantly inhibit its activation and improve the renal pathology of lupus mice, providing a new idea for the treatment of lupus disease mediated by basophil activation. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 These are the results of proteomic detection and verification of basophil activation intervention, where A is the result of proteomic detection of basophil activation intervention; and B is the result of proteomic verification of basophil activation intervention by protein immunoblotting.

[0024] Figure 2 This is the plasmid map of the recombinant plasmid for knocking down human basophil EXOSC3.

[0025] Figure 3Figure 3 shows the effect of knocking down human basophil EXOSC3 on its activation, where A is the flow cytometric graph of IL-4 expression level after knocking down basophil EXOSC3; B is the statistical graph of IL-4 expression level after knocking down basophil EXOSC3; C is the flow cytometric graph of IL-6 expression level after knocking down basophil EXOSC3; D is the statistical graph of IL-6 expression level after knocking down basophil EXOSC3; E is the flow cytometric graph of IL-13 expression level after knocking down basophil EXOSC3; F is the statistical graph of IL-13 expression level after knocking down basophil EXOSC3; P<0.05 indicates significant difference, marked with *.

[0026] Figure 4 Figure 3 shows the effect of knocking down human basophil EXOSC3 on T cell activation, where A is the flow cytometric graph of T cell activation indicator CD25; B is the statistical graph of T cell activation indicator CD25; C is the flow cytometric graph of T cell activation indicator CD44; D is the statistical graph of T cell activation indicator CD44; E is the flow cytometric graph of T cell activation indicator CD69; F is the statistical graph of T cell activation indicator CD69; P<0.05 indicates significant difference, marked with *.

[0027] Figure 5 This is the plasmid map of the recombinant plasmid for knocking down mouse basophil Exosc3.

[0028] Figure 6 Gating scheme and purity test for flow cytometry sorting of mouse bone marrow induced basophils.

[0029] Figure 7 Effects of adoptive transfer of Exosc3 knockdown basophils on renal pathology in lupus mice. DETAILED DESCRIPTION

[0030] To better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. It should be understood by those skilled in the art that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0031] Unless otherwise specified, the experimental methods used in the examples are conventional methods; the materials, reagents, etc. used, unless otherwise specified, can be obtained from commercial sources. The nucleotide sequence of human EXOSC3 can be found in the NCBI sequence NM_016042.4, and the nucleotide sequence of mouse Exosc3 can be found in the NCBI sequence NM_001362788.1.

[0032] Example 1: EXOSC3 is a key protein regulating basophil activation

[0033] The experimental intervention methods are as follows:

[0034] (1) Extraction of human basophils

[0035] 1) Place the human peripheral blood in the EDTA anticoagulant tube into a 15 mL centrifuge tube and add 1 mL of HetaSep TM Solution, mix thoroughly by inverting, centrifuge (90g, 5min, room temperature), and let stand at room temperature for 10min;

[0036] 2) Use a 3 mL Pasteur tube to slowly transfer the plasma to a 50 mL centrifuge tube and add 4 times the volume of EasySep TM Buffer, mix thoroughly by inversion, and centrifuge (120g, 10min, room temperature);

[0037] 3) Remove the supernatant with a 3 mL Pasteur tube and add EasySep TM Resuspend in buffer and centrifuge (120 g, 10 min, room temperature);

[0038] 4) Repeat step 3);

[0039] 5) Remove the supernatant with a 3 mL Pasteur tube and use 1.5 mL EasySep TM Resuspend PBMC in Buffer and transfer PBMC to the flow tube using a 200 μL pipette;

[0040] 6) Counting: Take 2 μL of PBMC suspension into a 200 μL Eppendorf tube and count with EasySep TM Buffer was diluted to 10 μL, 10 μL trypan blue was added, and the mixture was gently pipetted with a 10 μL pipette. 10 μL was taken to a counting plate for counting and detection of cell activity.

[0041] 7) Adjust the cell concentration to 5×10 7 cells / mL, add 50 μL of primary antibody per mL, gently pipette to mix, let stand for 7 minutes, add secondary antibody of the same system (vortex for 30 seconds before adding), and isolate PBMC with EasySep TM Resuspend the solution in Buffer to 2.5 mL and immediately place it in a magnet. After standing for 3 minutes, pour the liquid directly into a new flow tube. Repeat this process once to obtain basophils.

[0042] (2) Proteomic detection and validation of activated human basophils

[0043] The basophils extracted in step (1) were divided into three groups: Control, Anti-IgE and Anti-IgE+CQ. The Control group did not receive any intervention; the Anti-IgE group was added with 1 μL / mL of Anti-IgE (Sigma, USA) and cultured for 24 hours to promote its activation; the Anti-IgE+CQ group was added with 1 μL / mL of Anti-IgE (Sigma, USA) and 1 μL / mL of CQ (Sigma, USA) and cultured for 24 hours to inhibit activation.

[0044] Subsequently, the three groups of basophils were sent to Shanghai Zhongke New Life Company for proteomics testing.

[0045] Finally, the proteomic results were verified by western blotting.

[0046] The experimental results are shown in Figure 1 Through cell activation-related cluster analysis, we screened out that EXOSC3 expression was enhanced when basophils were activated, while its expression was weakened after inhibiting activation. The above results suggest that EXOSC3 is a key protein regulating basophil activation.

[0047] Example 2: Intervention of human basophil EXOSC3 to inhibit its activation level

[0048] The basophils extracted in step (1) of Example 1 were grouped into: Control, Anti-IgE, and Anti-IgE+EXOSC3 KD There were three groups: the Control group did not receive any intervention; the Anti-IgE group was added with 1 μL / mL Anti-IgE (Sigma, USA) and cultured for 24 hours to promote its activation; the Anti-IgE+EXOSC3 KD EXOSC3 was knocked down in the basophils of the group, and then 1 μL / mL of Anti-IgE (Sigma, USA) was added and cultured for 24 hours.

[0049] The knockdown process of human basophil EXOSC3 is as follows:

[0050] Preparation of knockdown EXOSC3 plasmid: insert the Homo-EXOSC3-sh3 sequence into the pLK0.1-U6-EF1a-copGFP-T2A-puro plasmid (purchased from Guangzhou Aiji Biotechnology Co., Ltd.). The plasmid map of the recombinant plasmid pLKO.1-U6-Homo-EXOSC3-sh3-EF1a-copGFP-T2A-puro can be found in Figure 2 ; The nucleotide sequence of Homo-EXOSC3-sh3 is:

[0051] ccggGCTTAATTAGAAAGCTATTAGCTCGAGCTAATAGCTTTCTAATTA AGCTTTTTgaatt (lowercase indicates the restriction site sequence).

[0052] Take 10 μl of celetrix electroporation solution A and electroporation solution B, mix them thoroughly, add human basophils, and then add 2 μg / uL knockdown EXOSC3 plasmid (pLKO.1-U6-Homo-EXOSC3-sh3-EF1a-copGFP-T2A-puro) and mix them evenly. Then add the mixed solution to a 20 μL electroporation tube, put the electroporation tube into the electroporation instrument, and set the electroporation parameters to 850V and a duration of 20ms.

[0053] Subsequently, the three groups of basophils were subjected to flow cytometry. The specific operation process of flow cytometry is as follows:

[0054] 1) Incubation with extracellular antibodies: Add extracellular staining antibodies (see Table 1) to the sample, incubate at 4°C for 30 min in the dark, and then wash twice with PBS.

[0055] Table 1 Staining antibodies and incubation system

[0056] Staining Antibodies Incubation system CD123APC-Cy7 (eBioscience, USA) 5μL / 100μL system CD203c PE (eBioscience, USA) 5μL / 100μL system

[0057] 2) Fixation / permeabilization: After extracellular staining, remove excess PBS, then add 1 mL of fixation / permeabilization solution (BD Biosciences, USA), shake and mix for 3 seconds, incubate at 4°C for 40-50 minutes in the dark.

[0058] 3) Membrane permeabilization / washing: Add 1 mL of membrane permeabilization / washing solution (BD Biosciences, USA) to the sample, centrifuge at 350 g, 4° C., for 6 min, discard the supernatant, and repeat twice.

[0059] 4) Incubation with intracellular antibodies: Add intracellular staining antibodies (see Table 2) to the sample, incubate at 4°C in a dark place for 30-50 min, and then wash twice with membrane permeabilization / cleaning solution (BD Biosciences, USA).

[0060] Table 2 Staining antibodies and incubation system

[0061] Staining Antibodies Incubation system IL-4PE-Cy7 (eBioscience, USA) 5μL / 100μL system IL-6APC (eBioscience, USA) 5μL / 100μL system IL-13FITC (eBioscience, USA) 5μL / 100μL system

[0062] 9) Flow cytometry detection: The samples were resuspended in 200 μL of membrane permeabilization / washing solution (BD Biosciences, USA) and detected using a BD FACS Celesta flow cytometer (BD Biosciences, USA).

[0063] The experimental results are shown in Figure 3 After knocking down EXOSC3 in basophils, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 were significantly reduced. The above results indicate that basophils promote their activation through EXOSC3.

[0064] Example 3: Basophils promote T cell activation via EXOSC3

[0065] The experimental method is as follows:

[0066] (1) Extraction of T cells:

[0067] 1) Extraction with PBS containing 2% FBS;

[0068] 2) Place the human peripheral blood in the EDTA anticoagulant tube in a 50 mL centrifuge tube, add PBS containing 2% FBS at a ratio of peripheral blood: PBS containing 2% FBS = 1:1, and mix thoroughly;

[0069] 3) Place the lymph separation solution in a 50 mL lymphatic tube, and slowly add the mixed solution in step 2) on top of the lymph separation solution using a 1 mL pipette tip at a ratio of lymph separation solution: peripheral blood: PBS containing 2% FES = 1:1:1;

[0070] 4) Centrifugation, 800g, 20min, room temperature;

[0071] 5) After centrifugation, remove the upper plasma layer, take the cloud layer peripheral blood mononuclear cells (PBMC) into a new 50 mL centrifuge tube, and wash with 4 times the system of PBS containing 2% FBS;

[0072] 6) Centrifugation, 3000 rpm, 10 min, room temperature, to remove platelets;

[0073] 7) Remove the supernatant and continue to resuspend and wash with PBS containing 2% FBS;

[0074] 8) Centrifugation, 1200 rpm, 10 min, room temperature;

[0075] 9) Remove the supernatant, resuspend the PBMCs with 1 mL-1.5 mL PBS containing 2% FBS, and place in a 5 mL flow tube;

[0076] 10) Count and adjust the cell concentration to 5×10 7 cells / mL, add 50μL Isolation Cocktail per mL, let stand at room temperature for 7 minutes, and then add RapidSpheres TM(Vortex for 15 seconds in advance). TM Resuspend the solution in Buffer to 2.5 mL, immediately place the flow tube in a magnet, let it stand for 3 min, pour the liquid into a new flow tube, continue to place it in the magnet and let it stand for 1 min, and finally obtain T cells.

[0077] (2) EXOSC3 knockdown and co-culture of basophils and T cells:

[0078] The knockdown EXOSC3 basophils prepared in Example 2 were added with 1 μL / mL Anti-IgE (Sigma, USA) and cultured for 24 hours, and then incubated with the T cells in step (1) at 37°C in an incubator containing 5% CO2 using an X-Vivo TM 15Medium, 1μg / mL IL-2, 10% fetal bovine serum and 1% double antibody were added for co-culture for 24 hours. At the same time, the Control group and Anti-IgE group without knockdown of basophil EXOSC3 were set up.

[0079] (3) Flow cytometry to detect T cell activation level:

[0080] 1) Extract the co-cultured T cells, add extracellular staining antibodies (see Table 3), incubate at 4°C for 30 min in the dark, and then wash twice with PBS.

[0081] Table 3 Staining antibodies and incubation system

[0082] Staining Antibodies Incubation system CD3 APC-Cy7 (BD Biosciences, USA) 5μL / 100μL system CD25BB515 (BD Biosciences, USA) 5μL / 100μL system CD44PE (BD Biosciences, USA) 5μL / 100μL system CD69APC (BD Biosciences, USA) 5μL / 100μL system

[0083] 2) Flow cytometric analysis: The samples were resuspended in 200 μL PBS (BD Biosciences, USA) and detected using a BD FACS Celesta flow cytometer (BD Biosciences, USA).

[0084] The experimental results are shown in Figure 4 , knocking down basophil EXOSC3 and co-culturing with T cells can significantly weaken the activation level of T cells. The above results show that basophils promote T cell activation through EXOSC3.

[0085] Example 4: Adoptive transfer of Exosc3 basophils improves renal pathology in pristane-induced lupus mice

[0086] The experimental intervention methods are as follows:

[0087] (1) Preparation of mouse basophils

[0088] Bone marrow was obtained from C57BL / 6J mice, induced to differentiate into basophils by IL-3, and sorted by flow cytometry to improve purity. The details are as follows:

[0089] ① Kill the mouse and soak it in 75% alcohol for at least 5 minutes. Peel the mouse's skin from the back, cut the mouse's thigh (including the pubic bone) (avoid cutting the bone marrow here to prevent alcohol from entering the bone marrow and causing bone marrow cell death), and soak the thigh in 75% alcohol for at least 2 minutes.

[0090] ② In the clean bench, transfer the mouse thigh from the alcohol to commercial PBS (in a culture dish) and wash off the alcohol. Transfer the mouse thigh to a clean culture dish, remove the mouse thigh muscle, and divide the bone into several sections. Use a 5mL syringe to aspirate PBS (or culture medium) and blow the bone marrow into the culture dish. Use about 15mL PBS for each mouse. After fully blowing the bone marrow fluid with a 1mL pipette, filter the bone marrow fluid into a 15mL EP tube with a 40μm filter, centrifuge: 1200g, 4℃, 10min, and remove the supernatant. Add 2mL of red blood cell lysis buffer (red blood cell lysis buffer is diluted with double distilled water at 1:9), lyse for 10min, centrifuge: 1200g, 4℃, 5min, and remove the supernatant.

[0091] ③Cell culture: prepare 50mL cell culture medium (10% FBS): 45mL culture medium (RPMI 1640 medium) + 5mL serum (100% FBS) + 500μL double antibody. Use 2 dishes to culture bone marrow induced cells from each mouse, and the IL-3 concentration of cell culture is 15ng / mL. Observe under a microscope whether the cells have been evenly seeded. Measure the number of cells and record them, and culture them in an incubator. It takes 9 days to induce basophils, and the liquid needs to be changed every 3 to 4 days, for a total of 2 changes during this period. Take out the cells that have been cultured for 3 days, collect the supernatant and centrifuge: 200g, room temperature, 5min. IL-3 needs to be added every time the liquid is changed, at a concentration of 15ng / mL.

[0092] ④Purification and verification of mouse basophils

[0093] On the 9th day of culture, the cells were collected in a 15 mL centrifuge tube and centrifuged at 200 g at room temperature for 5 min. The supernatant was removed and the cells were resuspended in 1 mL of RPMI 1640 medium and transferred to a flow tube.

[0094] Each 1×10 6Add 0.5μL BV421 Hamster Anti-Mouse FcεR1α, 0.5μL BV510 Hamster Anti-Mouse CD49b, 0.5μL BB700 Rat Anti-Mouse CD117, and 1.25μL APC anti-mouse CD11c Antibody to each cell and incubate at room temperature in the dark for 30 minutes. Add 3mL RPMI 1640 medium to wash, centrifuge at 350g, room temperature, for 8 minutes, remove the supernatant, repeat washing twice, and resuspend in 1mL RPMI 1640 medium.

[0095] The labeled basophils were sorted by flow cytometry, and the gates were set as: FcεRI + CD117 - CD11c - CD49b + After sorting, select some cells for purity verification, and set the gate as: FcεRI + CD49b + , obtain basophils with purity > 90%, the results are shown in Figure 6

[0096] (2) Construction of Exosc3 knockdown mouse basophils:

[0097] Preparation of knockdown Exosc3 plasmid: Insert the Mus-Exosc3-sh2 sequence into the pLK0.1-U6-EF1a-copGFP-T2A-puro plasmid (purchased from Guangzhou Aiki Biotechnology Co., Ltd.). The plasmid map of the recombinant plasmid pLKO.1-U6-Mus-Exosc3-sh2-EF1a-copGFP-T2A-puro can be found in Figure 5 ;

[0098] The nucleotide sequence of the Mus-Exosc3-sh2 is:

[0099] ccggGGTGCTGAATCAGGTGGTTCTCTCGAGAGAACCACCTGATTCAG CACCTTTTTgaatt (lowercase indicates the restriction site sequence).

[0100] Take 10 μL of celetrix electroporation solution A and electroporation solution B, mix them thoroughly, add mouse basophils, and then add 2 μg / μL knockdown Exosc3 plasmid (pLKO.1-U6-Mus-Exosc3-sh2-EF1a-copGFP-T2A-puro), and mix them evenly. Then add the mixed solution to a 20 μL shock tube, put the shock tube into the electroporation instrument, and set the electroporation parameters to 850V and a duration of 20ms.

[0101] (3) Pristane-Mcpt8 flox / flox,CAGGCre-ERTM Construction of Lupus Mice:

[0102] Basophil-deficient mice (Mcpt8) were purchased from Saiye Biotechnology Co., Ltd. flox / flox,CAGGCre-ERTM ) and control mice (Mcpt8 flox / flox Pristane-Mcpt8 was constructed by intraperitoneal injection of pristane flox / flox,CAGGCre-ERTM Lupus mice were then adoptively transferred with Exosc3 knockdown basophils (Baso-Exosc3 KD ) to observe the role of Exosc3. At the same time, a disease control group (control) and a healthy control group (Mcpt8 flox / flox ).

[0103] (4) Pristane-Mcpt8 flox / flox,CAGGCre-ERTM Renal Pathology Assessment in Lupus Mice:

[0104] PAS staining was used to perform pathological staining on mouse kidney tissue sections. PAS staining steps: ① Dewaxing: xylene 10min×2 times; ② Hydration: 100% alcohol 10s→95% alcohol 10s→wash with water 30s; ③ 1% periodic acid 25min→wash with water 30s; ④ PAS staining solution 30min→soak in water 2min; ⑤ Nuclear staining: hematoxylin 6min→wash with water 3 times, about 5min→1% hydrochloric acid alcohol 2s→wash with water 2s→1% ammonia water 2s→wash with water 2s; ⑥ Cytoplasm staining: 1% eosin 4min→wash with water 1min; ⑦ 100% alcohol 2s→dry and seal the slide; ⑧ Observe and take pictures under a microscope to evaluate kidney pathology.

[0105] The experimental results are shown in Figure 7 After adoptive transfer of Exosc3-knockdown basophils, the brush border shedding of the mouse kidneys was significantly improved. It can be seen that lupus nephritis can be significantly improved. The above results indicate that basophil activation promotes the progression of lupus nephritis through Exosc3.

[0106] In summary, the expression of EXOSC3 is enhanced after basophil activation, and the expression is decreased after basophil activation is inhibited. After knocking down EXOSC3 in basophils, the expression levels of inflammatory factors IL-4, IL-6 and IL-13 are significantly reduced. After knocking down EXOSC3 in basophils and co-culturing with T cells, the activation level of T cells can be significantly reduced. Finally, adoptive transfer of Exosc3 knockdown basophils into lupus mice showed that it can significantly improve the renal pathology of lupus mice. In short, basophils promote their activation through EXOSC3, thereby promoting the progression of lupus nephritis, and knocking down Exosc3 basophils can significantly improve the renal pathology of lupus mice. The present invention provides a new idea for the treatment of lupus disease mediated by basophil activation.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. Use of basophils intervening in the expression of EXOSC3 in the preparation of a drug for preventing and / or treating lupus nephritis, characterized in that: The intervention includes knocking down or knocking out the expression of EXOSC3.

2. The use according to claim 1, characterized in that: The method for knocking down the expression of basophil EXOSC3 includes using CRISPR-Cas9 technology to perform gene editing, and using siRNA, plasmid-mediated shRNA or virus-mediated shRNA to silence EXOSC3.

3. The use according to claim 2, characterized in that: The nucleotide sequence of the shRNA is: GCTTAATTAGAAAGCTATTAGCTCGAGCTAATAGCTTTCTAATTAAGCTTTTT or GGTGCTGAATCAGGTGGTTCTCTCGAGAGAACCACCTGATTCAGCACCTTTTT.

4. Use of basophil EXOSC3 as a target in the preparation of reagents for preventing and / or treating lupus nephritis.

5. Use of inhibitors targeting basophil EXOSC3 expression in the preparation of drugs for preventing and / or treating lupus nephritis.

6. The use according to any one of claims 1 to 5, characterized in that: The basophils are basophils derived from peripheral blood.

7. A preparation for preventing and / or treating lupus nephritis, characterized in that: These include agents that knock down or eliminate basophil EXOSC3 expression.

8. The preparation according to claim 7, characterized in that The substance for knocking down the expression of basophil EXOSC3 is siRNA, dsRNA, shRNA, miRNA or antisense nucleic acid.

9. The preparation according to claim 8, characterized in that The nucleotide sequence of the shRNA is: GCTTAATTAGAAAGCTATTAGCTCGAGCTAATAGCTTTCTAATTAAGCTTTTT or GGTGCTGAATCAGGTGGTTCTCTCGAGAGAACCACCTGATTCAGCACCTTTTT.

10. The preparation according to claim 7, characterized in that Also included are pharmaceutically acceptable carriers.

Citation Information

Patent Citations

  • Application of autophagy inhibitor in preparation of medicament for inhibiting basophilic granulocyte activation

    CN111012783A

  • Transcriptome expression profile of activated basophilic granulocyte and construction method and application thereof

    CN111304293A

  • New therapies involving miRNA-193a

    CN114729358A

  • Compositions and methods for treating or preventing lupus

    US20140127199A1

  • METHOD OF SEQUENCING AND IDENTIFYING RNAs

    WO2015181397A1

Cited By

  • Application of intervention basophilic granulocyte ABHD18 in preparation of medicine for treating pneumonia

    CN122424369A

  • Application of intervening basophilic granulocyte RNA methylation in preparation of medicine for treating LN

    CN122479120A